Search

RSV and influenza detections hit record low levels in 2020

Western Australia has experienced historically low levels of respiratory syncytial virus (RSV) and influenza this winter due to the public health measures implemented to prevent the spread of COVID-19.

Help us build a new weapon in the fight against deadly flu

At just two years old, Lucy lost her fight against flu. With your generous help, we can finally beat influenza.

Australian parents oblivious to true danger of the flu

New research investigating the devastating impact of the 2017 flu season by PAEDS-FluCAN, a national collaboration observing influenza in children, confirmed it was time to take action after thousands of children were hospitalised with the virus last year.

Time running out to prepare for flu season

People are being urged to ensure they've had their vaccination with the 'flu season expected to hit in Western Australia within weeks.

Latest news & events

Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.

Researchers share their expertise with the community in Cockburn

Researchers from the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia have shared their expertise with the community in Cockburn, covering topics ranging from respiratory disease in babies to recurring ear infections in kids.

Warm Welcome for the Neonatal Infection and Immunity Team

Clinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.

Targeting interventions to improve influenza control: a proof of principle geomapping study

Christopher Kefyalew Hannah Blyth Alene Moore MBBS (Hons) DCH FRACP FRCPA PhD BSc, MPH, PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers

Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network

Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.

Platform trial in COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity and reactogenicity of licensed COVID-19 booster vaccines in immunocompetent individuals >12 years old. Here, we present data for seven different vaccines among three pre-specified participant strata defined by age and primary vaccine schedule.